Placebo + Resmetirom
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Fatty Liver Disease
Conditions
Non-Alcoholic Fatty Liver Disease
Trial Timeline
Dec 16, 2019 → Jan 6, 2023
NCT ID
NCT04197479About Placebo + Resmetirom
Placebo + Resmetirom is a phase 3 stage product being developed by Madrigal Pharmaceuticals for Non-Alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04197479. Target conditions include Non-Alcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04197479 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Alcoholic Fatty Liver Disease